Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study.
Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, Goh SY, Thuresson M, Chen H, Surmont F, Hammar N, Fenici P; CVD-REAL Investigators and Study Group. Kosiborod M, et al. Among authors: karasik a. J Am Coll Cardiol. 2018 Jun 12;71(23):2628-2639. doi: 10.1016/j.jacc.2018.03.009. Epub 2018 Mar 11. J Am Coll Cardiol. 2018. PMID: 29540325 Free article. Clinical Trial.
Linkage of the Dinuclear Gold(I) Complex Luminescence and Origin of Endocyclic Amino Group of Cyclic P2N2-Bridging Ligands.
Strelnik ID, Dayanova IR, Faizullin BA, Mustafina AR, Gerasimova TP, Kolesnikov IE, Islamov DR, Litvinov IA, Voloshina AD, Sapunova AS, Gubaidullin AT, Musina EI, Karasik AA. Strelnik ID, et al. Among authors: karasik aa. Inorg Chem. 2023 Dec 4;62(48):19474-19487. doi: 10.1021/acs.inorgchem.3c02437. Epub 2023 Nov 20. Inorg Chem. 2023. PMID: 37983813
ROS-producing nanomaterial engineered from Cu(I) complexes with P2N2-ligands for cancer cells treating.
Faizullin BA, Dayanova IR, Kurenkov AV, Gubaidullin AT, Saifina AF, Nizameev IR, Kholin KV, Khrizanforov MN, Sirazieva AR, Litvinov IA, Voloshina AD, Lyubina AP, Sibgatullina GV, Samigullin DV, Musina EI, Strelnik ID, Karasik AA, Mustafina AR. Faizullin BA, et al. Among authors: karasik aa. Discov Nano. 2023 Oct 30;18(1):133. doi: 10.1186/s11671-023-03912-7. Discov Nano. 2023. PMID: 37903946 Free PMC article.
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: karasik a. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Schechter M, Melzer Cohen C, Zelter T, Yanuv I, Rozenberg A, Chodick G, Karasik A, Mosenzon O. Schechter M, et al. Among authors: karasik a. Diabetes Obes Metab. 2023 Oct;25(10):3054-3058. doi: 10.1111/dom.15172. Epub 2023 Jun 29. Diabetes Obes Metab. 2023. PMID: 37385956 No abstract available.
212 results